Although endogenous ligands for Toll-like receptor (TLR)4-myeloid differentiation factor 2 (MD2) have not been well-understood, we here report that a globo-series glycosphingolipid, globotetraosylceramide (Gb4), attenuates the toxicity of lipopolysaccharides (LPSs) by binding to TLR4-MD-2. Because α1,4-galactosyltransferase (A4galt)-deficient mice lacking globo-series glycosphingolipids showed higher sensitivity to LPS than wild-type mice, we examined mechanisms by which globo-series glycosphingolipids attenuate LPS toxicity. Cultured endothelial cells lacking A4galt showed higher expression of LPS-inducible genes upon LPS treatment. In turn, introduction of A4galt cDNA resulted in the neo expression of Gb4, leading to the reduced expression of LPS-inducible genes. Exogenous Gb4 induced similar effects. As a mechanism for the suppressive effects of Gb4 on LPS signals, specific binding of Gb4 to the LPS receptor TLR4-MD-2 was demonstrated by coprecipitation of Gb4 with recombinant MD-2 and by native PAGE. A docking model also supported these data. Taken together with colocalization of TLR4-MD-2 with Gb4 in lipid rafts after LPS stimulation, it was suggested that Gb4 competes with LPS for binding to TLR4-MD-2. Finally, administration of Gb4 significantly protected mice from LPS-elicited mortality. These results suggest that Gb4 is an endogenous ligand for TLR4-MD-2 and is capable of attenuating LPS toxicity, indicating the possibility for its therapeutic application in endotoxin shock.
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innate immunity | sepsis A lthough the existence of endogenous ligands for Toll-like receptor (TLR)4 has been assumed such as fatty acids and phospholipids, their nature and implication in the sterile inflammation referred to as homeostatic inflammation have not been well-understood (1) .
Glycosphingolipids (GSLs) are presented mainly on the cell surface and play a variety of roles in the cell (2) . Among functions demonstrated so far, their roles as receptors for bacterial toxins are the most clear in terms of their specificity (3) . In particular, a family of bacterial toxins designated A1B5 such as cholera toxin and clostridium toxins showed similar patterns of attachment and invasion into cells (4) .
Globo-series GSLs have a common core structure, namely Galα1,4-Galβ1,4-Glc-ceramide (globotriaosylceramide; Gb3), synthesis of which is catalyzed by α1,4-galactosyltransferase (A4galt) using lactosylceramide (LacCer) as a precursor ( Fig. 1) (5) . Gb3 is also named CD77 (6), and has been studied as a tumor antigen of Burkitt lymphoma (7) and germ cell-derived tumors (8) . It is also expressed in a particular population of B lymphocytes in germinal centers (9) and on kidney proximal tubules and intestinal epithelial cells (10) . Gb3 has been considered to be a receptor for verotoxins secreted by pathogenic Escherichia coli O157 (11) , and its expression corresponds to the main pathological sites in hemolytic and uremic syndrome (12) . However, one of the main targets of verotoxins is the endothelium, as shown by A4galt knockout (KO) mice (13) , suggesting that globo-series GSLs are highly expressed on endothelial cells.
In studies of Gb3 expression in the endothelium under pathological conditions, it has been reported that inflammatory cytokines such as TNF-α induced Gb3 expression on endothelial cells (13) . Thus, we expected that coexistence of lipopolysaccharide (LPS) might enhance toxic effects of verotoxins. Then, we examined responses of A4galt KO mice to injected LPS. Contrary to our expectation, A4galt KO mice were more sensitive to injected LPS, resulting in earlier death than wild-type (WT) mice. We therefore investigated involvement of globo-series GSLs in the regulation of toxic activity of LPS.
Results
A4galt-Deficient Mice Showed Higher Sensitivity to Injected LPS in the Shwartzman Reaction than WT Mice. As shown in Fig. 1A , Gb3 is synthesized from LacCer by A4galt. This is the first step in the synthesis of globo-series GSLs. From Gb3, Gb4 is synthesized by β1,3-N-acetylgalactosaminyltransferase (Gb4 synthase, B3galnt1). To determine the implications of induction of globo-series GSLs in response to LPS, we assessed the sensitivity of mice to the generalized Shwartzman reaction, which is a well-characterized test for LPSinduced lethal shock (14) . After injection of low-dose LPS (0.25 mg/ kg), a high dose of LPS (25 or 37.5 mg/kg) was injected (Fig. 1B) . A4galt-deficient mice succumbed easily to the Shwartzman reaction compared with WT mice (Fig. 1C) , suggesting that globo-series GSLs play a protective role in LPS-induced lethal shock.
Expression of LPS-Inducible Genes Was Augmented in Vascular
Endothelial Cells from A4galt-Deficient Mice. Because we expected the role of globo-series GSLs in vascular endothelial cells (mECs) in the protection against LPS, we compared the responsiveness to LPS between A4galt-deficient and WT cells by establishing a primary culture of mECs. As shown in Fig. 2A , CD31/PECAM-1 (an endothelial cell marker) was expressed in almost all cells. When treated with LPS, mECs from A4galt-deficient mice showed increased expression of LPS-inducible genes, such as inflammatory cytokines (Tnf and Il6), chemokines, and NO synthesis-related genes (Nos2 and Irf1), compared with those from WT mice (Fig.  2B ). Increased production of iNOS protein and nitric oxide (NO) in response to LPS/IFN-γ was also demonstrated in A4galt-deficient mECs (Fig. 2C) . Suppressive effects of globo-series GSLs on LPS-inducible signals were not observed in macrophages and spleen cells (Fig. S1 ).
Gb4 Was Expressed in mECs and Enhanced by LPS. We performed flow cytometry to examine GSLs expressed on the surface of mECs. As previously reported (15) , definite induction of A4galt in response to LPS was seen (Fig. 2D ) with no appearance of Gb3 (Fig. 2E) . A4galt was actually induced by LPS, whereas B3galnt1 showed no change (Fig. 2D) . On the other hand, Gb4 was expressed in resting mECs. TLC/orcinol spray and TLC immunostaining of extracted glycolipids revealed that Gb4 was expressed in mECs ( Fig. 2 E and F) . Correspondingly, we observed that cell-surface expression of Gb4 was enhanced at 48 h after LPS stimulation in WT mECs (Fig. 2G) . Accordingly, the amounts of Gb4 increased dependent upon the dosage of LPS (0111:B4, Re595), as shown by TLC immunostaining (Fig. 2H ). Faint reaction with anti-Gb4 mAb is explained in Fig. S2 .
Suppressive Effects of A4galt and Exogenous Gb4. Effects of Gb4 are described in Figs. S3 and S4.
No Differences in LPS Binding and Expression Levels of TLR4-MD-2
Complex. Equivalent expression of LPS receptors and their genes in two cell types is described in Fig. S5 .
Binding of LPS to MD-2 Protein Generated from Insect Cells. Based on the similarity of the 3D structure of MD-2 to that of ganglioside GM2 activator protein (GM2AP) (Fig. S6 ), we hypothesized that Gb4 binds to MD-2 so that it can act as a competitive inhibitor for LPS, leading to the suppression of LPS signals. To investigate whether Gb4 can be an endogenous ligand for MD-2, we generated recombinant mouse soluble V5-His 6 -tagged MD-2 protein using a baculovirus expression system ( Fig. S7 A-C).
Binding of Recombinant MD-2 with [
3 H]Gb4 in Vitro. We synthesized radioactive Gb4 by the glycosyltransferase reaction (Fig. 3A) . To examine whether MD-2 directly binds to Gb4, we incubated a recombinant mouse MD-2 protein with radioactive Gb4, and the MD-2 protein was pulled down by an anti-V5 antibody. Radioactivity of immunoprecipitates was counted, and significant radioactivity could be detected (Fig. 3B) . To examine the binding specificity between MD-2 and Gb4, we performed a cold inhibition assay using nonradioactive GSLs as inhibitors. As expected, the binding of mouse MD-2 protein to Gb4 was specifically perturbed by nonradioactive Gb4 as well as LPS (Fig. 3C) . The binding between MD-2 protein and Gb4 was not inhibited with any other GSLs examined, except for partial perturbation by GA1.
Identification of GSLs Bound to MD-2. We performed TLC immunostaining and lipid analysis with mass spectrometry (MS) using secreted FLAG-His 6 tag of C-terminus of mMD-2 (MD-2-FLAG-His 6 ) from the Gb4-positive endothelial cell line UV♀2 to identify MD-2-bound endogenous GSLs. TLC immunostaining revealed that only Gb4 was precipitated by MD-2-FLAGHis 6 (Fig. 3D) . Nanoelectrospray ionization MS and a neutralloss scanning MS 2 analysis of the peaks conducted in positive-ion mode revealed carbohydrates composed of one HexNAc-hexose. An MS 3 analysis revealed that subsequently appeared components with two hexoses and ceramide were of Gb4 composed of a sphingoid base of d18:1 and C24:0 fatty acid (Fig. 3E) . Interestingly, a peak of Gb4 with d18:1-C24:1 could not be detected in the precipitates despite its presence in the whole extract (Fig.  S8 ). Due to very low amounts of sample, we could not perform MS 3 analysis to identify other molecular species of Gb4. Gb4 could not be detected in eluates derived from control culture supernatant (details for MS are in Fig. S8 and SI Methods).
Complex Formation of TLR4-MD-2 with Gb4. We investigated whether the TLR4-MD-2 complex multimer could be formed after the binding of Gb4. As for LPS, dimerized TLR4-MD-2 complexes formed by the addition of E. coli LPS Re595 migrated more slowly than monomeric complexes in native PAGE (Fig.  4A) . To examine the binding of Gb4 to MD-2, complex formation of TLR4-MD-2 with GSLs was analyzed after the incubation of each GSL with TLR4-MD-2. A band shift of TLR4-MD-2 was detected after incubation with Gb4 at a relatively high dose. In contrast, migration of TLR4-MD-2 did not change after incubation with Gb3 or LacCer (Fig. 4B) . K D values were 1.072 μM (Re595 vs. TLR4-MD-2) and 238.1 μM (Gb4 vs. TLR4-MD-2) as calculated by Scatchard plot analysis using bands in native PAGE (Fig. 4 C and D) .
Furthermore, we investigated the mode of inhibition of LPS binding to TLR4-MD-2 with Gb4. Results of binding kinetics and a Lineweaver-Burk plot suggested that the effect of Gb4 on TLR4-MD-2 was of noncompetitive inhibition (Fig. 4 E and F) , namely that Gb4 might compete with LPS by binding in the vicinity of the MD-2 pocket (SI Methods).
Docking Model Revealed Specific Binding of Gb4 to MD-2. To examine the possibility that Gb4 binds to the hydrophobic cavity in MD-2, in silico docking of Gb4 to MD-2 was performed using the Molecular Operating Environment (MOE). Detailed methods are described in SI Methods. As shown in Fig. 5A , the lipid IVa binding site on MD-2 might be shared with Gb4, although their binding was not mutually competitive. It was noted that the ceramide moiety of Gb4 was embedded in the hydrophobic cavity of MD-2 (Fig. 5C ), as lipid IVa was (Fig. 5B) . The docking simulation was also examined in the TLR4-MD-2 complex (Protein Data Bank ID code 3FXI). Detailed analyses of direct interaction between human MD-2 and Gb4 following the known accommodation site for LPS (16, 17) will be reported elsewhere. Consequently, not only the ceramide portion of Gb4 but also its carbohydrate moiety showed significant hydrogen bonds to be reactive with several amino acids in TLR4-MD-2 and MD-2.
Colocalization of TLR4-MD-2 and Gb4 in mECs. It has been reported that the TLR4-MD-2 complex is not present basically in the glycolipid-enriched microdomain (GEM)/rafts (15) but is recruited to GEM/rafts after LPS stimulation in macrophages (18) . Under resting conditions, TLR4 and Gb4 seemed not to be merged, but colocalization could be seen at 5-15 min after LPS stimulation (Fig. S9) .
Administration of Gb4 Protected Mice from LPS Toxicity. We tried to examine the therapeutic consequence of systemic administration of Gb4 to endotoxin shock model mice. We used the D-galactosamine (D-GalN)-primed endotoxin shock model because D-GalN priming can enhance LPS-elicited mortality at a reduced amount (<10 −4 ) of LPS (Fig. 6A) (19) . As expected, administration of Gb4 at 4 h after D-GalN/LPS injection obviously allowed mice to survive much longer than that of PBS with 0.05% Tween-20 (PBS-T) (Fig. 6B) . LDH release from liver after D-GalN/LPS treatment was also much lower in Gb4-treated than in PBS-T-treated mice (Fig. 6C) . Pathological study of the lung at 6.5 h after D-GalN/LPS injection revealed lymphocyte infiltration through the pulmonary vessels with marked thickening of the alveolar membranes (Fig. 6D, Left) . In contrast, there is almost no congestion or infiltration of lymphocytes into the lung at 6.5 h after D-GalN/LPS injection followed by injection of Gb4 in PBS-T (Fig. 6D, Right) . Sections of liver at 6.5 h after D-GalN/LPS injection followed by PBS-T showed massive congestion and proapoptotic morphology such as nuclear concentration, vacuolation, and round-shaped parenchymal cells throughout the tissues. More than 90% of areas of degeneration of parenchyma were observed with less than 5% of hemorrhagic areas (Fig. 6F, Left) . In contrast, proapoptotic features of parenchymal cells were seen in 20-30% of parenchyma, and more than 70% appeared normal in the Gb4-treated group (Fig. 6F,  Right) . Only spotty necrosis of hepatocytes and little vacuoleforming cells were seen in the liver of Gb4-treated mice. At 72 h after D-GalN/LPS injection, massive necrosis associated with intralobular hemorrhage and prominent vacuole formation spreading radially around the central vein was frequently seen (Fig. 6G, Left) . In contrast, no severe degeneration was found in the Gb4-treated group (Fig. 6G, Right) .
Discussion
Neutral GSL analysis revealed that the main structure in endothelial cells was Gb4, not Gb3. We also showed that the up-regulated enzyme after stimulation with LPS was A4galt. These results are consistent with a recent report that Gb4 was induced in response to TNF-α in human umbilical vein endothelial cells (20) . Gb4 is the most prominent neutral GSL in human erythrocytes (21) and is an essential structure of blood group P antigen (22) . The physiological function of Gb4 in vivo has not been demonstrated, although it has been shown to be an adhesion molecule on epithelial cells for bacteria (23) , cancer cells (24) , and some toxins (25) . On the other hand, endogenous ligands for particular carbohydrate structures have long been expected to be present in mammalian cells. Consequently, TLR4-MD-2 is an example of a definite endogenous ligand for GSLs. Yamakawa et al. first discovered a neutral glycolipid in human erythrocytes and named it "globoside" (26) . Now the physiological function of Gb4 and/or its involvement in pathological processes has been elucidated.
Although it was reported recently that MD-2 plays a principal role in recognizing LPS (16, 27) , many kinds of hydrophobic biomolecules including nonself ligands and endogenous ligands have been reported to bind to TLR4-MD-2, such as the antitumor agent Taxol, β-defencin, HSP70, saturated fatty acid, and so forth (28) . In turn, MD-2 belongs to the MD-2-related lipidrecognition family, which consists of MD-1, MD-2, the mite allergen Derf2, lysosomal cholesterol-binding protein NPC2, and ganglioside GM2AP (29) . GM2A is a kind of coenzyme that plays a role in the β-hexosaminidase digestion of GM2 in lysosomes (30) . Thus, this family of molecules plays roles in the interaction between proteins and GSLs. Based on the well-matched 3D structures between GM2A and MD-2 (Fig. S6) , we examined the binding of MD-2 to Gb4. The specificity of binding between Gb4 and TLR4-MD-2 was high (Fig. 4) . As expected, the glycolipid structure, including the carbohydrate moiety, could fit well into the hydrophobic cavity of MD-2, supporting the specificity of Gb4 binding to MD-2. The docking model using reported structures of crystallized MD-2 (16) strongly suggested that Gb4 specifically bound to MD-2 (Fig. 5) , although the binding sites of Gb4 and LPS were not identical (Fig. 4 E and F) . The precise binding site of Gb4 on TLR4-MD-2 remains to be investigated.
The binding affinity based on the K D values obtained by the kinetics study with native PAGE indicated that the K D of Gb4 to TLR4-MD-2 was 238.1 μM, whereas that of LPS (Re595) to TLR4-MD-2 was 1.072 μM. Therefore, the intensity of binding between a single Gb4 and the TLR4-MD-2 complex should be much weaker than that between LPS and TLR4-MD-2. On the other hand, the presence of Gb4 on the cell surface definitely affected the toxicity of LPS and its signals (Fig. 2) . Clustered Gb4 on the cell membrane should amplify the binding reaction with TLR4-MD-2 and increase its biological significance. K D values might vary depending on differences in assay systems and LPS source (31) . SDS/PAGE under nonreducing conditions revealed that most of the secreted MD-2 exists in a multimerized form, which is known to lack ability to bind LPS. In contrast, the MD-2 monomer, which has the ability to bind LPS, was present in very small quantities in secreted MD-2 from Sf9 insect cells as previously reported (32) . This could be a reason for the low binding between Gb4 and MD-2 (Fig. 3B) .
To elicit the signaling mediated by LPS receptors, it is necessary for LPS to be shuttled to the TLR4-MD-2 complex through LPS transfer proteins such as LPS-binding protein (LBP), glycosylphosphatidylinositol (GPI)-anchored CD14, or soluble CD14. The role of LBP is to bring LPS to the cell surface and form a ternary complex with CD14. Consistent with several reports and the results in Fig. S5C , endothelial cells lack GPI-anchored CD14 and thus require soluble CD14 released from cells bearing GPIanchored CD14 to react with LPS (33) .
Recently, it was reported that the RP105-MD-1 complex, a homolog of TLR4-MD-2, was expressed in adipose tissue-associated macrophages and might receive endogenous ligands derived from adipocytes, leading to chronic inflammation (34) . Thus, pattern-recognition receptors in innate immune systems certainly recognize noninfectious endogenous ligands and contribute to the pathogenesis of inflammatory diseases. In addition, mice lacking the majority of gangliosides show abnormal activation of glial cells (35) , suggesting novel roles of gangliosides in the regulation of noninfectious inflammation in brain tissues.
Eritoran is a competitive inhibitor for TLR4-MD-2, and has been expected to be a protective drug for endotoxin shock. However, there were no differences in the effect on saving lives between eritoran and a placebo. Because the timing of administering drugs seems to be critical for eliciting therapeutic consequence, it is worth considering the fact that systemic administration of Gb4 allowed D-GalN-primed endotoxin shock model mice to survive even at 4 h after LPS injection.
Taken together, these data suggest that Gb4 is an endogenous ligand for TLR4-MD-2. Because most identified endogenous ligands of TLRs are stimulatory on immune cells, effects of Gb4 demonstrated in this study might be unique, suggesting that Gb4 can be used for the treatment of LPS-induced inflammatory reactions and endotoxin shock caused by Gram-negative bacillus infection.
Methods
Mice. The mutant mice used in this study were generated and maintained in our laboratory as described previously (13) . All experimental protocols were approved by the Animal Experimental Committee of the Graduate School of Medicine, Nagoya University, along the guidelines of the Japanese government, and were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Antibodies. Polyclonal rabbit anti-TLR4 rodent-specific antibody was purchased from Cell Signaling Technology. Polyclonal rabbit anti-mouse TLR4 antibody was from Abcam. Derivations of other antibodies are described in SI Methods. 
